Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated inflammatory disease

Current Allergy and Asthma Reports

Volumn 8, Issue 4, 2008, Pages 277-287

  Bingham, Clifton O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BELATACEPT; BELIMUMAB; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOMODULATING AGENT; LEFLUNOMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; OMALIZUMAB; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; AUTOANTIBODY; CYTOKINE; DERMATOLOGICAL AGENT; ENZYME INHIBITOR; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AZOOSPERMIA; BACTERIAL INFECTION; BASOPHIL DEGRANULATION; BEHCET DISEASE; BODY FAT DISTRIBUTION; BONE MARROW SUPPRESSION; BONE NECROSIS; BULLOUS SKIN DISEASE; CATARACT; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CHRONIC URTICARIA; CINCA SYNDROME; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; CROHN DISEASE; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; ENTERITIS; EYE TOXICITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GOUT; GRAFT REJECTION; GRANULOMATOSIS; HEMORRHAGIC CYSTITIS; HISTAMINE RELEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LEPROSY; LEUKOPENIA; LIVER FUNCTION TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; MODERATE PERSISTENT ASTHMA; MONOTHERAPY; MOUTH ULCER; MUCKLE WELLS SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OVARY INSUFFICIENCY; PEMPHIGUS; PLEURA EFFUSION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; UVEITIS; WEIGHT GAIN; B LYMPHOCYTE; BLOOD; CHRONIC DISEASE; DRUG ANTAGONISM; GRANULOCYTE; IMMUNOLOGY; MAST CELL; METABOLISM; PATHOPHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN PRESENTATION; AUTOANTIBODIES; B-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; DERMATOLOGIC AGENTS; ENZYME INHIBITORS; GRANULOCYTES; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MAST CELLS; T-LYMPHOCYTE SUBSETS; URTICARIA;

EID: 50349097577     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0046-2     Document Type: Review

References (70)

1. Grob JJ, Revuz J, Ortonne JP, et al.: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005, 152:289-295.
2. Delong LK, Culler SD, Saini SS, et al.: Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008, 144:35-39.
3. Di Lorenzo G, Pacor ML, Mansueto P, et al.: Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006, 31:327-334.
4. Powell RJ, Du Toit GL, Siddique N, et al.: BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007, 37:631-650.
5. Doutre MS: Chronic urticaria and thyroid auto-immunity. Clin Rev Allergy Immunol 2006, 30:31-37.
6. O'Donnell BF, O'Neill CM, Francis DM, et al.: Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999, 140:853-858.
7. Marsland AM: Autoimmunity and complement in the pathogenesis of chronic urticaria. Curr Allergy Asthma Rep 2006, 6:265-269.
8. Puccetti A, Bason C, Simeoni S, et al.: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005, 35:1599-1607.
9. Vasagar K, Vonakis BM, Gober LM, et al.: Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006, 36:770-776.
10. Eckman JA, Hamilton RG, Gober LM, et al.: Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008 (Epub ahead of print).
11. Vonakis BM, Saini SS: Basophils and mast cells in chronic idiopathic urticaria. Curr Allergy Asthma Rep 2005, 5:270-276.
12. Caproni M, Giomi B, Volpi W, et al.: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005, 114:284-292.
13. Kuek A, Hazleman BL, Ostor AJ: Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007, 83:251-260.
14. Brightling C, BArry M, Amrani Y: Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008, 121:5-10.
15. Bach JF: Infections and autoimmune diseases. J Autoimmun 2005, 25(Suppl):74-80.
16. Haas N, Iwen W, Grabbe J, et al.: MHC class II antigen expression is increased in different forms of urticaria. Int Arch Allergy Immunol 1996, 109:177-182.
17. Pacor ML, Di Lorenzo G, Mansueto P, et al.: Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm 2006, 2006:62489.
18. Ying S, Kikuchi Y, Meng Q, et al.: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109:694-700.
19. Garmendia JV, Zabaleta M, Aldrey O, et al.: Immunophenotype characteristics of peripheral blood mononuclear leukocytes of chronic idiopathic urticaria patients. Invest Clin 2006, 47:361-369.
20. Toubi E, Adir-Shani A, Kessel A, et al.: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 2000, 20:371-378.
21. Grammer LC, Shaughnessy MA, Harris KE, et al.: Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2000, 85:368-371.
22. Oskeritzian CA, Zhao W, Min HK, et al.: Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol 2005, 115:1162-1168.
23. Yasnowsky KM, Dreskin SC, Efaw B, et al.: Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol 2006, 117:1430-1434.
24. Lourenco FD, Azor MH, Santos JC, et al.: Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 2008 (Epub ahead of print).
25. Vonakis BM, Vasagar K, Gibbons SP Jr, et al.: Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007, 119:441-448.
26. Sabroe RA, Poon E, Orchard GE, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484-493.
27. Staumont-Salle D, Dombrowicz D, Capron M, et al.: Eosinophils and urticaria. Clin Rev Allergy Immunol 2006, 30:13-18.
28. Caproni M, Giomi B, Melani L, et al.: Cellular infiltrate and related cytokines, chemokines, chemokine receptors and adhesion molecules in chronic autoimmune urticaria: Comparison between spontaneous and autologous serum skin test induced wheal. Int J Immunopathol Pharmacol 2006, 19:507-515.
29. Kyburz D, Brentano F, Gay S: Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 2:458-459.
30. Nosal R, Drabikova K, Pecivova J: Effect of chloroquine on isolated mast cells. Agents Actions 1991, 33:37-40.
31. Reeves GE, Boyle MJ, Bonfield J, et al.: Impact of hydroxychloroquine therapy on chronic urticaria: Chronic autoimmune urticaria study and evaluation. Intern Med J 2004, 34:182-186.
32. Harrison CA, Bastan R, Peirce MJ, et al.: Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 2007, 150:509-518.
33. Grattan CE, O'Donnell BF, Francis DM, et al.: Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000, 143:365-372.
34. Vena GA, Cassano N, Colombo D, et al.: Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006, 55:705-709.
35. Kessel A, Bamberger E, Toubi E: Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study. J Am Acad Dermatol 2005, 52:145-148.
36. Shahar E, Bergman R, Guttman-Yassky E, et al.: Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006, 45:1224-1227.
37. Moder KG: MycopheNolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003, 90:15-19.
38. Clunie GP, Lennard L: Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004, 43:13-18.
39. Malaviya R, Uckun FM: Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N- [3-(trifluoromet hyl)phenyl] propenam ide inhibits IgE/FcepsilonRI receptormediated mast cell leukotriene release and allergic asthma in mice. Am J Ther 2001, 8:309-316.
40. Sawamukai N, Saito K, Yamaoka K, et al.: Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 2007, 179:6479-6484.
41. Vincenti F, Larsen C, Durrbach A, et al.: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770-781.
42. Chamian F, Lowes MA, Lin SL, et al.: Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005, 102:2075-2080.
43. St Clair EW, Tedder TF: New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum 2006, 54:1-9.
44. Levesque MC, St Clair EW: B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121:13-21.
45. Joly P, Mouquet H, Roujeau JC, et al.: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
46. Simon D, Hosli S, Kostylina G, et al.: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122-128.
47. Looney RJ, Srinivasan R, Calabrese LH: The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008, 58:5-14.
48. Boyce JA: Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006, 117:1415-1418.
49. Metz M, Bergmann P, Zuberbier T, et al.: Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008, 63:247-249.
50. Spector SL, Tan RA: Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-193.
51. Sands MF, Blume JW, Schwartz SA: Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007, 120:979-981.
52. Noga O, Hanf G, Brachmann I, et al.: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006, 117:1493-1499.
53. Cassano N, D'Argento V, Filotico R, et al.: Low-dose dapsone in chronic idiopathic urticaria: Preliminary results of an open study. Acta Derm Venereol 2005, 85:254-255.
54. Engin B, Ozdemir M: Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008, 22:481-486.
55. Baccarani M, Cilloni D, Rondoni M, et al.: The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
56. Juurikivi A, Sandler C, Lindstedt KA, et al.: Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: A potential approach to the treatment of arthritis. Ann Rheum Dis 2005, 64:1126-1131.
57. Rothenberg ME, Klion AD, Roufosse FE, et al.: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
58. Magerl M, Philipp S, Manasterski M, et al.: Successful treatment of delayed pressure urticaria with anti-TNFalpha. J Allergy Clin Immunol 2007, 119:752-754.
59. Goldbach-Mansky R, Dailey NJ, Canna SW, et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592.
60. Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006, 8(Suppl 2):S3.
61. Smolen JS, Beaulieu A, Rubbert-Roth A, et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
62. McGirt LY, Vasagar K, Gober LM, et al.: Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006, 142:1337-1342.
63. Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65:168-173.
64. Gach JE, Sabroe RA, Greaves MW, et al.: Methotrexateresponsive chronic idiopathic urticaria: A report of two cases. Br J Dermatol 2001, 145:340-343.
65. Godse K: Methotrexate in autoimmune urticaria. Indian J Dermatol Venereol Leprol 2004, 70:377.
66. Pavy S, Constantin A, Pham T, et al.: Methotrexate therapy for rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:388-395.
67. Rudick RA, Stuart WH, Calabresi PA, et al.: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
68. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
69. Khalili K, White MK, Lublin F, et al.: Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007, 68:985-990.
70. O'Dell JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004, 350:2591-2602.